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31.1 INTRODUCTION
Hyperthermia is a method for the treatment of malignant
tumors that artificially elevates target tissue temperatures.
Hyperthermia using magnetic particles was first proposed
in the 1950s by Gilchrist et al. [1] and is still under devel-
opment today [2]. It has recently attracted considerable
interest as a novel cancer treatment, as compared with
radiotherapy and chemotherapy it causes virtually no side
effects to other organs, as well as being relatively nonin-
vasive [3]. The efficiency of this type of thermotherapy
has been demonstrated for several types of cancers,
including brain, prostate, and breast cancers [3].
Treatment by hyperthermia kills cancer cells in tumors
by heat irradiation. The technique consists of targeting mag-
netic nanoparticles (MNPs) toward tumor tissue followed
by the application of an external alternating magnetic field
(AMF) that generates heat via two mechanisms: (1) hystere-
sis losses of the ferromagnetic particles; and/or (2) Néel and
Brownian relaxation by superparamagnetic particles
through targeting [4], which heats the tissue containing the
MNPs (Fig. 31.1) [2,5,6]. The temperature in the tumor tis-
sue increases to 4146C [7] causing the necrosis of the
cancer cells (cell processes up to apoptosis), while leaving
the surrounding healthy tissue undamaged. In addition to
this direct effect, tumor-specific immune responses, includ-
ing heat-shock protein expression, have been observed dur-
ing in vivo and in vitro experiments, demonstrating the
potential of this therapy to act not only locally, but also at
distant sites including metastatic cancer cells [8].
Two types of heating treatments are currently per-
formed: (1) hyperthermia at 4146C which stimulates
the immune response for nonspecific immunotherapy; and
(2) thermoablation at 4656C, aimed at initiating cell
necrosis, coagulation, or carbonization for tumor destruc-
tion [3,9].
The characteristic temperature of tumor cell thermoa-
blation is very close to that of normal cells, making tem-
perature control unnecessary. MNPs can act as nanoscale
mediators converting electromagnetic energy into heat
when exposed to an external electrical or magnetic field
after injection as the particles are dispersed. However,
inductive hyperthermia (with MNPs) seems currently
more useful, as body tissue susceptibility is very low and
does not constitute a heat source in a magnetic field [10].
Nevertheless as a rule, MNPs are toxic for living organ-
isms. This means that the magnetic particles must be
coated with, or encapsulated into, biocompatible materials
during or after synthesis in order to prevent (1) changes to
their initial state, (2) the formation of large aggregates, and
(3) biodegradation due to interactions with the biological
system.
For in vivo biomedical applications, the MNPs
employed must be nontoxic, nonimmunogenic, and small
enough to pass through the capillary systems of organs and
tissues, thus remaining in circulation after injection and
avoiding the embolism of blood vessels. They should also
have a high level of magnetization so that their motion in
the blood can be controlled by varying the magnetic field,
thus enabling them to be delivered to the site of the diseased
tissue [11].
In this context, composite materials from iron oxide/
biomaterials or iron oxide/hydroxyapatite (HA) are typi-
cally used for hyperthermia treatment [12], although
nickel and cobalt oxide composites also have appropriate
ferromagnetic properties for hyperthermia applications at
physiological temperature [13].
Iron oxides, such as magnetite (Fe3O4) or γ-hematite
(γ-Fe2O3), are commonly used as thermoseeds for hyper-
thermia due to their biodegradable nature, biocompatibil-
ity, and superparamagnetic effects, i.e., they generate heat
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when subjected to alternate magnetic fields [1417].
Fe3O4 is widespread in the environment, despite the fact
that it is less thermodynamically stable than γ-Fe2O3 in
the presence of oxygen [18]. The long-term instability of
the properties of MNPs has led researchers to study
γ-Fe2O3. The disadvantage of the slightly lower bulk satu-
ration magnetization of this iron oxide [19,20] is compen-
sated by its greater stability.
Nonetheless, Fe3O4 microspheres have also been
developed [2123], since they exhibit an embolization
effect by blocking the blood vessels near the tumors and
consequently shutting off the supply of nutrients to the
cancer cells.
Iron oxide particles are used at a nanoscale (iron nano-
particles—INPs) for hyperthermia applications, and it has
been observed that many of the particular properties of
INPs with diameters between 6 and 30 nm can be modi-
fied, e.g., their superparamagnetism properties can be
improved and the saturation field (the external field
needed for saturation magnetization) raised [2426].
INPs usually exhibit superparamagnetic behavior,
due to their small volume, meaning that their thermal
energy may be enough to spontaneously change the
degree of magnetization within each INP. In other
words, the magnetic moment of each INP is able to
rotate randomly (relative to the orientation of the INP)
simply because of its temperature. For this reason, in the
absence of an electromagnetic field, the net magnetic
moment of a system containing INPs will be zero at high
enough temperatures [27].
However, in the presence of a field, there will be a net
statistical alignment of magnetic moments, analogous to
what happens to paramagnetic materials, except that now
the magnetic moment is not that of a single atom, but of
MNPs containing various atoms, making each moment up
to 104 times larger than for a paramagnetic material [27].
The properties described above enable the real-time
in vivo monitoring of MNP distribution [28,29].
Nonetheless, the nanosized magnetite particles tend to
aggregate because of their high specific area and strong
interparticle interactions, which limits their use [30].
Thus, in order to ensure stability and nontoxicity under
physiological conditions, as well as to allow for functio-
nalization and targeting, these materials must be coated or
encapsulated. These coatings or encapsulants should ide-
ally have a high affinity for the iron oxide core, be non-
immunogenic and nonantigenic, and prevent opsonization
by plasma proteins [31]. Materials used as coatings or
encapsulants include liposomes, lipids, dendrimers, pro-
teins, polyethylene glycol, polysaccharides, polyacryl-
amide, bisphosphonates, silicon dioxide [32], noble
metals (Au and Ag) [33], and titanium dioxide [31],
resulting in the development of composite materials com-
posed of INPs and biopolymers.
In addition, the poor solubility and stability in water
of INPs at physiological pH may be prevented by coating
them with a water-soluble polymer [34,35]. For example,
biocompatible polymers have been used as coatings, since
they can be bound to drugs, antibodies, enzymes, proteins,
or nucleotides, and can be directed to an organ, tissue, or
tumor using an external magnetic field. However, some
studies have shown that a nonpolar coating made from
fatty acids could improve the antitumor properties of
MNPs [36].
31.2 SYNTHESIS OF IRON
NANOPARTICLES (INPS)
The performance of INPs is dependent on the chemical
and physical characteristics of MNPs and their surfaces,
which are themselves greatly influenced by the method of
synthesis chosen for their preparation [37]. The control of
particle size, shape, distribution, crystallinity, and colloi-
dal and magnetic properties, such as saturation magnetiza-
tion and susceptibility, is crucial. The method of synthesis
must then permit the tailoring of the size and surface
chemistry of the MNPs in order to meet specific demands
for physical and biological applications [37].
FIGURE 31.1 Magnetic targeting. No accumulation of MNPs occurs
in the absence of a magnetic field, whereas under the influence of this
field, MNPs alone or in combination with therapeutic cargo accumulate
at a destined site. This includes the brain. Targeting efficiency of MNPs
can be further improved by modifying the MNP surface using cell-
specific targeting moieties, for instance, transferrin for brain targeting.
MNPs, magnetic nanoparticles.
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INPs may be synthesized by various methods such as
coprecipitation, hydrothermal, laser pyrolysis, solgel,
and biopolymer-inducing procedures, or sonochemical
synthesis [24,3845]. The first two of these methods are
the ones most commonly used.
31.2.1 Coprecipitation
The most efficient and easiest method is to coprecipitate
the magnetite using soluble salts in water (e.g., chloride,
nitrate) [41,43] using one of two procedures:
1. The controlled oxidation of an Fe21 aqueous solution
in an alkaline medium, to produce Fe21 and Fe31 at a
molar ratio of 1:2 [40]. In this case, because controlled
oxidation of Fe21 is very difficult to obtain, only
Fe3O4 results;
2. The addition of a high pH (alkaline) solution to an
aqueous mixture of Fe21 and Fe31 at a molar ratio of
1:2 [38,39,44,4648]:
Fe21 1 2Fe31 1 8OH2-Fe3O4 1 4H2O (31.1)
This reaction takes place at pH5 914, under a non-
oxidizing, oxygenfree environment.
However, if oxygen is present, Fe3O4 is oxidized to
Fe(OH)3:
Fe3O4 1 1=2O2 1 4H2O-3Fe OHð Þ3 (31.2)
And under air conditions, FeO from Fe3O4 is oxidized
forming a pure Fe2O3 phase:
2 FeO  Fe2O3ð Þ1 1=2O2-3Fe2O3 (31.3)
Thus, under aerobic conditions pure magnetite is not
obtained due to the oxidation process. To avoid this incon-
venience the reaction can be conducted under an inert
nitrogen (N2) atmosphere [49,50]. Distilled water degassed
with N2 can also be used for the preparation of an aqueous
solution. After precipitation, the magnetite is calcinated
under an N2 atmosphere.
By coprecipitating in a highly basic aqueous medium
the magnetite nanoparticles (MNPs) acquire negative
charges on their surfaces, preventing their agglomeration
by repulsion phenomena. The negativity of the magnetite
surfaces increases with the alkalinity of the aqueous
medium.
This process, which involves the formation of interme-
diate hydroxyl species, is affected by experimental para-
meters such as temperature, pH, the concentration of the
cations, and the nature of the base, which greatly influ-
ence average MNP size in the range of 320 nm. It is
noteworthy that pH is a particularly critical parameter
affecting both MNP size (an increase in the pH induces
repulsion among primary MNPs giving smaller magnetite
MNPs) and their stable dispersion. In particular, thanks to
electrostatic surface repulsion phenomena, stable ionic
ferrofluids can be obtained over a wide pH range. The
coprecipitation approach offers many advantages includ-
ing: the use of cheap chemicals and mild reaction condi-
tions; the possibility to directly synthesize the INPs in
water; the ease of scale-up; and the production of highly
concentrated ferrofluids due to the high density of
surface hydroxyls. Most importantly, the synthetic route
is extremely flexible when it comes to the modulation of
core and surface properties. Conversion to maghemite is
easily obtained by the chemical oxidation of the magne-
tite colloids, and substituted ferrites can be prepared by
the alkalinization of aqueous mixtures of a ferric salt and
a salt of a divalent metal under boiling conditions [51].
Likewise, thanks to the high density of reactive sites, sur-
face modification can be easily performed by the direct
incorporation of additives, which is particularly useful for
large-scale production as is the case of the carbonate
method [52]. A general limitation of the hydrolytic
approach lies in the large number of parameters, which
have to be carefully monitored in order to control the
synthetic outcome, resulting from the complex aqueous
chemistry and rich phase diagram of the iron oxide
phases.
As a major drawback of hydrolytic routes lies in the
limited control of MNP size distribution, synthesis in con-
fined environments, such as microemulsions, has been
proposed. In particular, reverse micelles have been used
to carry out the classic coprecipitation reaction [53] and
the hydrolysis of metalsurfactant complexes [54] in
water-in-oil emulsions. The parameters that affect MNP
size are: (1) the microstructure and composition of the
microemulsion, including both the surfactant [most com-
monly sodium bis(2-ethylhexyl) sulfosuccinate (AOT),
cetyl trimethylammonium bromide or dodecyl sulfonate
(DS)], and the hydrocarbon that constitutes the continuous
phase (such as hexane, heptane, octane); (2) the tempera-
ture; and (3) the type of counterion. Reverse micelles
have been successfully employed as a means to mediate
the formation of iron oxide MNPs, as well as substituted
ferrites with an improved size distribution in the 412 nm
range (typical size of the water-in-oil microemulsion
droplets) [5558].
In addition to improving the magnetic properties of
the synthesized MNPs the coprecipitation method can
be performed under hydrothermal conditions [53].
Hydrothermal routes have also been used for hydrolytic
procedures starting from iron complexes, such as the age-
ing of iron polyolates in aqueous acidic/basic solutions,
followed by digestion in autoclave at 80150C for sev-
eral days [54]. In this approach reaction conditions, such
as the solvent used, temperature, and time, generally sig-
nificantly affect the synthetic outcome. The size of the
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crystallized MNPs is controlled mainly through the com-
peting rate processes of nucleation and particle growth.
31.2.2 Hydrothermal Method
The hydrothermal method is used to obtain many fine
metal oxide particles with various shapes and morpholo-
gies, which have a significant influence on their proper-
ties. This method uses a pressure higher than 1 atm.
coupled with a low synthesis temperature (100500C)
without subsequent heat treatments, and with different
plateaus. Some of the advantages of this method are: no
organic reagents are used; it is relatively cost-effective; a
high particle crystallinity is achieved with the possibility
of efficiently controlling the size and desired morphology
of the resulting materials (e.g., nanorods, nanowires,
nanotubes, nanobelts, necklace, and hollow nanospheres);
good dispersion characteristics are obtained (e.g., mono-
dispersion); high yields of the desired products are easily
attained [5965]. In addition, this method uses water-
soluble salts, and the reaction generally takes place in an
alkaline medium under an N2 atmosphere. Finally, an
aqueous solution may be prepared using distilled water
degassed with N2 (for 30 minutes or 1 hour) and surfac-
tants or templates used for obtaining the mesoporous
magnetite.
31.3 MAGNETITE: TUMOR TREATMENT
USING AN EXTERNAL MAGNETIC FIELD
Metal-based nanoscale particles possess unique optoelec-
tronic or magnetic properties that make them highly
promising as imaging agents in cancer therapy research
[6672]. Inspired by physiologically existing nanoma-
chines, NPs are designed to safely reach their target and
release their cargo at the specific site of the disease,
thus increasing tissue bioavailability of the drug
employed. The site-specific delivery of therapeutics to
tumors is accomplished through both active and passive
mechanisms.
With their unique structural properties of high surface
to volume ratio and hollow structure, nanomaterials
can carry an extremely high drug payload [15,73,74].
Nanomaterials with specific optical or magnetic charac-
teristics may also be regulated by radiation or magnetic
fields for the controlled release of drug molecules [75,76].
NPs are able to target cancer cells by simply being
accumulated and entrapped in tumors (passive targeting).
This phenomenon is called “the enhanced permeation and
retention (EPR) effect,” and is caused by leaky angioge-
netic vessels and poor lymphatic drainage. The EPR
effect has been used to explain why macromolecules and
NPs are found at higher ratios in tumors compared to nor-
mal tissues [77]. The exploitation of this effect requires
the careful selection of the size of the NPs, so that they
extravasate leaky tumor vasculature but are themselves
retained in the tumor due to insufficient lymphatic drain-
age [78]. NPs between 100 and 200 nm have been shown
to accumulate in tumors by the EPR effect, and the reten-
tion of large molecules is typically higher than that of
small molecules which can more easily diffuse back into
the vasculature. As well as having an appropriate size,
NPs must achieve an optimum concentration gradient
over a sustained time period of at least 6 hours to allow
for a long circulation time [76].
31.4 IN VIVO STUDIES DEMONSTRATING
THE ANTICANCER EFFECTS OF MAGNETIC
NANOCARRIERS
Kawai et al. [79] demonstrated, using a rat model, that
hyperthermia employing magnetic cationic liposomes
(MCLs) is an effective therapy for prostate cancer. MCL
therapy acted either directly by killing rat prostate cancer
cells in vivo after heating to 45C, or indirectly by inducing
an immune response. MCLs have a positive surface charge
and generate heat in an AMF due to hysteresis losses.
Tumor regression and the presence of CD3, CD4, and CD8
immunocytes were observed in the hyperthermic group.
HSP70 also appeared at the boundary between the viable
and necrotic areas. Induction of antitumor immunity by
intracellular hyperthermia using MCLs was also demon-
strated for solid T-9 rat glioma tissues. Treated tumor tissue
disappeared completely in many rats exposed to the AMF
(118 kHz, 384 Oe), generated three times for 30 minutes
each at 24-hour intervals. Untreated solid tumors on the
opposite side also disappeared completely, even though
MCLs were not injected into them. To examine whether a
long-lasting, tumor-specific immunity could be generated,
the rats cured by the hyperthermia treatment were
rechallenged with T-9 cells 3 months later. After a period
of transient growth, all the tumors disappeared.
Immunocytochemical assays revealed that the immune
response induced by the hyperthermia treatment was medi-
ated by both CD81 and CD41 T cells accompanied by a
marked augmentation of tumor-selective cytotoxic T lym-
phocyte activity. These results suggest that magnetic parti-
cles are potentially effective tools for the hyperthermic
treatment of solid tumors, as in addition to killing the tumor
cells by heating, a host immune response is induced [80].
Ito et al. [81] constructed anti-HER2 immuno-liposomes
containing magnetite NPs, which act as tumor-targeting
vehicles, thus combining anti-HER2 antibody therapy with
hyperthermia. The magnetite NP-loaded anti-HER2
immuno-liposomes exerted HER2-mediated antiprolifera-
tive effects on SKBr3 breast cancer cells in vitro. Around
60% of the magnetite NPs were incorporated into the
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SKBr3, and the cells were then heated to 42.5C under an
AMF, resulting in strong cytotoxic effects. These results
suggest that this novel therapeutic tool may be effectively
used to treat HER2-overexpressing cancer [81].
In another study, dextran magnetite was incorporated
into liposomes in order to obtain thermosensitive
magneto-liposomes which proved to exhibit anti-tumoral
effects on AH60C rat tumors, (the tumors were treated
with 15 mg iron/cm3 and exposed to a 500 kHz electro-
magnetic field generated by inductive heating). A temper-
ature of 42C was maintained for 7 minutes inside the
tumor, without affecting the surrounding tissues. The
tumor cells disappeared completely in the treated animals
and survival rates were significantly higher than those of
the control group [82].
31.5 IN VITRO STUDIES DEMONSTRATING
IMPROVEMENTS IN THE UPTAKE RATE OF
ANTICANCER AGENTS LOADED ONTO
NANOPARTICLES IN DIFFERENT TUMOR
CELLS
Hu et al. [83] synthesized tamoxifen-loaded magnetite/poly
(L-lactic acid) composite nanoparticles (TMCN) with an
average size of approximately 200 nm, in order to study
their in vitro anticancer activity against MCF-7 breast
cancer cells. The superparamagnetic property (saturation
magnetization value of approximately 7 emu/g) of the
TMCN was provided by Fe3O4 NPs of approximately
6 nm encapsulated in the poly(L-lactic acid) matrix. The
uptake rate of the TMCN and tamoxifen by the MCF-7
cells was estimated from the intracellular iron concentra-
tion. Significant changes in MCF-7 tumor cell morphology
were discernible from phase contrast microscopy after only
4 hours incubation with the TMCN, and approximately
80% of cells were killed after 4 days incubation [83].
Temperature-sensitive poly(N-isopropylacrylamide-
acrylamideallylamine)-coated iron oxide magnetic
nanoparticles (TPMNPs), prepared by the free radical
polymerization of monomers on the surface of silane-
coupled INPs, were cytocompatible and effectively taken
up by advanced thyroid cancer (ATC) cells in a dose-
dependent manner. An external magnetic field signifi-
cantly increased NP uptake, especially when the cells
were exposed to physiological flow conditions. Drug
loading and release studies using doxorubicin confirmed
the temperature-responsive release of the drugs from the
NPs. In addition, the doxorubicin-loaded NPs killed sig-
nificantly more ATC cells compared to free doxorubicin.
These in vitro results indicate that TPMNPs have poten-
tial as carriers for the controlled and targeted delivery of
drugs for thyroid cancer treatment [84].
In another study, Sun and Liang [85] compared the
antitumor activity of cisplatin or cis-diaminodichloroplatin
(CDDP)-loaded liposomes with NPs in vitro. These authors
demonstrated that nanocarriers with similar pharmaceutical
parameters can induce differences in cellular internaliza-
tion and elimination, which eventually influence antitumor
activity. Compared to gelatin NPs, liposome is preferable
for cisplatin delivery [85].
Currently, most research is focused on the design and
engineering of new scalable and economically viable mul-
tifunctional (multiplex) systems, capable of: identifying
malignant cells by molecular detection; visualizing their
location in the body using contrast-enhanced medical
imaging techniques; killing diseased cells with minimal
side effects through selective drug targeting and monitor-
ing treatment in real time [86]. The in vivo fate and func-
tions of NPs ultimately depend on their interactions with
blood proteins, and in this context coating the NPs
strongly influences their cellular uptake rate.
31.6 SATURATED FATTY ACIDS AS
COATINGS FOR MAGNETIC
NANOPARTICLES WITH IMPROVED
ANTICANCER DRUG CARRIER PROPERTIES
Saturated fatty acids (SFAs) account for 30%40% of the
total amount of Fatty acids (FAs) in animal tissues and
are distributed in palmitic acid (15%25%), stearic acid
(10%20%), myristic acid (0.5%1%), and lauric acid
(less than 0.5%). Palmitic and stearic acids are universally
found in natural fats [87,88], whilst lauric acid is specifi-
cally abundant in copra (39%54%) and palmist oils
(44%51%). Myristic acid and short-chain fatty acids
(including butyric acid) represent about 10% each of the
FAs in milk fat. The body is also capable of synthesizing
SFAs. The SFAs C12:0 to C18:0 can be converted to their
respective monounsaturated analogues by the action of
Δ9-desaturase (stearoyl-CoA desaturase—SCD). Myristic
and palmitic acids are involved in the fatty acid acylation
of proteins, which involves N-terminal myristoylation to
the NH2-terminal glycine, and side-chain palmitoylation
by the posttranslational formation of a thioester linkage
between the side-chains of cysteine and palmitic acid
[89,90].
Myristoylation induces protein activation, the myris-
toyl moiety being involved in the mediation of protein
subcellular localization, proteinprotein interactions, or
proteinmembrane interactions. About 0.5% of human
proteins (structural proteins, components of intracellular
signaling pathways, oncogenes, partially caspase-
degraded actin, gelsolin, protein kinases) [9194], but
also viral proteins, can be myristoylated [95].
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The association of proteins with the palmitoyl moiety
is reversible and facilitates proteinmembrane interac-
tions and the subcellular trafficking of proteins (e.g., the
α subunit of many heterotrimeric G proteins) [96]. SFAs
(C10:0C18:0) can also elevate or activate transcription
factors (PGC-1β, SREBP family), consequently increasing
the transcription of lipogenic target genes (FAS, SCD-1).
Coactivation of the nuclear receptor LXR/RXR may pro-
mote VLDL secretion. Palmitate induced the recruitment
of several transcription factors, such as NF-κB, hepato-
cyte nuclear factor 4 (HNF4), CEBPα, and PPARα [97].
SFAs (but also monounsaturated FAs) are known to
bind HNF4. In liver cells, palmitate and oleate have been
shown to inhibit the transcription of the glucose-6-
phosphatase gene [98].
SFAs, either free or linked to the lipid A moiety of
lipopolysaccharides, also indirectly induce NF-κB
nuclear translocation, activation, and expression of COX-
2 and other pro-inflammatory cytokines, through the
recently described toll-like receptor 4-derived signaling
pathways [99]. Butyric acid is an inhibitor of histone dea-
cetylase activity, with consequences for the structure of
chromatin [100]. The inhibition of histone deacetylase
can stimulate cellular differentiation, arrest growth, and
promote apoptosis in a variety of cancer cells [101] by
different mechanisms, for example, NF-κB activation, by
affecting histone activity, or ceramide de novo synthesis
[102104]. A recent study showed that fatty acid biosyn-
thesis and fatty acid desaturation was profoundly modi-
fied during the senescence process in cultured human
fibroblasts [105].
It is commonly recognized that SFAs play a role in
debilitating age-related illnesses such as type-2 diabetes
and coronary heart disease. Elevated concentrations of
palmitic acid are toxic to mitochondria and endoplasmic
reticulum and can induce apoptosis without the involve-
ment of reactive oxygen species. Changes in fatty acid
composition with aging are consistent with a reduction in
the activity of the stearoyl-CoA-desaturase 1 (SCD1)
gene and consequent increases in the concentrations of
palmitic and stearic acids relative to palmitoleic and oleic
acids. The reduced activity of SCD1 is an outcome of p53
activation and has an ongoing effect on mitochondrial and
cell functions [106]. Stearic acid has been proved to have
a neutral effect on cholesterol, but could be pro-lipogenic
thus acting as a stimulating factor for VLDLTAG
[107,108]. Studies on rats have shown that lauric acid
could be a precursor for ω3 fatty acid biosynthesis, for
example, α-linolenic acid, by successive Δ6-desaturation,
elongation, Δ5-desaturation, and two final elongations
[109].
Thermally stable poly[aniline-co-sodium N-(1-one-
butyric acid) aniline]-coated Fe3O4 MNPs, employed as
praclitaxel (PTX) carriers, were more stable at 37C than
free PTX (57-hour vs 19-hour at 37C). The PTX carriers
also showed a longer circulation time and lower IC50 than
free PTX in human prostate carcinoma cells: PC3 and
CWR22R, respectively. The application of a magnetic
field resulted in an even lower IC50 [110].
Oleic acid-coated and pluronic-stabilized MNPs pro-
duced an increase in circulation time in mice, and when
doxorubicin and PTX were incorporated into these MNPs,
synergistic antiproliferative effects were observed [111].
NPs incorporating palmitoyl ascorbate have been
proved to enhance the antitumor activity of ascorbate,
which at high doses acts as a prooxidant in tissue fluids
and delivers peroxide to tissues and fluids. The peroxide
is then detoxified by erythrocytes and plasma catalase in
normally perfused areas, but can kill cancer cells under
in vitro conditions [112].
31.7 THE FABRICATION AND
CHARACTERIZATION OF MAGNETITE
COATED WITH A NONPOLAR SHELL
WITHOUT USING AN EXTERNAL
MAGNETIC FIELD, AND IN VITRO ASSAYS
OF ITS ANTITUMOR ACTIVITY
It is well known that free ferrous iron (Fe21) can partici-
pate in the Fenton reaction, producing the highly toxic
hydroxyl radical (OH). This could favor the appearance
of malignant cells by inducing DNA lesions [113]. On the
other hand, cancer cells are generally deficient in the anti-
oxidant enzymes present in normal cells [114] making
them vulnerable to iron-mediated oxidative assaults.
Thus, iron overload in tumor cells could constitute a suc-
cessful therapeutic approach for the treatment of cancer
[115]. A few studies have shown that the passive accumu-
lation of INPs in tumor cells could have an antitumor
effect. For example, the injection of NPs containing the
equivalent of total iron body stores into athymic nude
mice bearing MCF-7 xenograft tumors decreased tumor
size and increased the animal’s survival [115]. While
MNPs passively localize tumors through the enhanced
permeability and retention effect, targeted formulations
may further increase the effectiveness of the proposed
therapy. The local delivery of iron-oxide through target-
ing by a magnetic field or by applying an adequate coat-
ing should thus be explored.
Fatty acids have been used in the design of solid lipid
NPs: a class of particulate drug carriers that remain in a
solid state at both room and body temperatures. Solid
lipid NPs have the advantage of combining physical sta-
bility with low toxicity and are increasingly used for the
protection of labile drugs from degradation in the body,
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and for their controlled and sustained release [116,117].
The application of lipid-based formulations for anticancer
drug delivery has overcome many obstacles commonly
found in conventional cancer chemotherapy, such as lim-
ited specificity, high toxicity, and the tendency to gener-
ate drug resistance [118,119].
31.8 BIOCOMPOSITES FROM IRON
NANOPARTICLES—BIOPOLYMERS
For biomedical applications, iron oxide MNPs must be
precoated with substances that assure their stability, bio-
degradability, and nontoxicity in physiological media in
order to achieve the combined properties of high magnetic
saturation, biocompatibility, and interactive surface func-
tions [120]. The size and surface properties of iron oxide
NPs can dramatically affect NP stability and efficiency.
MNPs should ideally be superparamagnetic and possess
high magnetization properties. This means that their
movements in the blood can be controlled with an exter-
nal magnetic field, and that they can be immobilized close
to the target tissue [121]. Surfactants are used to coat
MNPs since they act as a steric barrier thus preventing
aggregation caused by magnetic dipoledipole attractions
between particles and avoiding opsonization [122]. In this
context, polymeric coatings provide a means to tailor the
surface properties of MNPs such as surface charge and
chemical functionality [123]. The iron oxide core can be
coated with polymers during the synthesis process, which
must be long-chain.
A few studies have been undertaken in which MNPs
were coated with a biocompatible shell [124], or embed-
ded in a polymer [125] to avoid aggregation and confer
biocompatibility [126]. Recently, Soleymani et al. [127]
reported that polymer-coated La0.73Sr0.27MnO3 NPs
may have potential applications in cancer hyperthermia
therapy and magnetically activated drug delivery.
Nevertheless, current magnetic drug delivery systems still
need to overcome some challenges including the
unacceptable coincidental heating of healthy tissue, diffi-
culties encountered in controlling drug release time and
the released amount, and cytotoxicity and biocompatibil-
ity issues. More extensive work in this direction is thus
required.
According to some reports [128], particles in the range
of 10100 nm appear to be ideal for biomedical use as
they are small enough to penetrate very narrow capillaries
within body tissues. This leads to a more effective distri-
bution, ensuring adequate blood circulation times. Biswas
et al. [129] investigated the loading and release capacity
of a test antibiotic, ciprofloxacin, in a grown polymer
embedded with La0.67Sr0.33MnO3 (LSMO) NPs, and its
effects on different microorganisms. The controlled
release profile of the loaded drug in distilled water was
investigated as a function of time as reported in Gupta
and Bajpai [130]. DC magnetization assays showed that
the grown polymer embedded with LSMO exhibited mag-
netic behavior similar to that of LSMO alone without pro-
ducing any significant changes to the Curie temperature
(TC). The hysteresis behavior of the parent sample was
also preserved with almost the same coercive field value,
but with a lower magnetic moment. The drug loading and
release experiments showed that after 8 h, c90% of the
ciprofloxacin loaded in the grown LSMO-embedded poly-
mer was released. The minimum inhibitory concentrations
of the loaded ciprofloxacin were studied for selected spe-
cies of Gram-positive and Gram-negative bacteria. Good
antibacterial activity was found against a Gram-positive
bacteria, Bacillus subtilis and a Gram-negative bacteria,
Salmonella typhi. These results are encouraging as the
antibacterial activity was comparable to that of free cipro-
floxacin for at least some of the bacterial strains. This
means that these particles may be used for magnetically
activated drug delivery whereby the drugs carried may be
released on reaching the intended diseased site in the
body. It must be mentioned that the focus of this study
was on drug loading and release. Obviously, other issues,
such as minimizing the side effects of the drug at the
target site, need to be addressed.
Among the coating materials studied to date, chitosan
(CS) is one of the most promising. CS prevents particles
reacting with blood proteins and receptors [131].
Aziz et al. [132] synthesized magnetic INPs by the copre-
cipitation method, due to its potential for large-scale
manufacturing, cost-effectiveness, ease of production, and
the hydrophilicity of the nanocrystals [133].
For biomedical applications, CS-coated MNPs are
generally synthesized by the in situ coating method, i.e.,
the alkaline coprecipitation of Fe21 and Fe31 precursors
in aqueous solutions of hydrophilic CS polymers. The
polymers limit the core growth of iron oxide during the
preparation, and stabilize, via steric repulsions, the dis-
persed NPs in the aqueous media [10]. The coprecipita-
tion method involves the precipitation of iron salts in the
presence of CS and trisodium phosphate, which cross-
links the adsorbed CS molecules to each other through an
ionic interaction.
Aziz et al. [132] evaluated the effectiveness of mag-
netic CS-coated INPs for biomedical applications. The
prepared biocomposite was characterized using several
analyses for comparative study. The coprecipitation
method used by these authors has some advantages over
previously published methods [134] as the process is
simple and can be performed under mild conditions
without using hazardous organic solvents. The authors
hypothesized that the ionically cross-linked CS NPs
would be more biocompatible than the covalently
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cross-linked CS NPs [135,136]. The X-ray diffraction
(XRD) patterns revealed that the iron oxide NPs had a
crystalline structure, whereas the CS coating gave a noisy
amorphous peak indicative of a noncrystalline material
[137]. Crystallite size as measured from X-ray powder
diffraction was about 13.4 nm, confirming its usefulness
for biomedical applications. Scanning electron micros-
copy (SEM) images of the CS-coated MNPs showed that
the particles were spherical. The FTIR spectra confirmed
the presence of metal-oxygen bonding.
Lyubutin et al. [138] developed hollow microcapsules
from biodegradable polyelectrolytes, poly-L-lysine (PLL)
and dextran sulfate (DS). The microcapsules were con-
structed using the layer-by-layer adsorption technique.
The capsule shells (PLL/DS)4 were modified with maghe-
mite NPs by in situ synthesis. XRD, High-resolution
transmission electron microscopy (HRTEM), Raman, and
Mössbauer spectroscopy data revealed that the INPs
exhibited the maghemite γ-Fe2O3 crystal structure.
Transmission electron microscopy (TEM) images showed
that the average diameter of the capsules was about
6.7 μm, while the average thickness of the capsule shell
was 0.9 μm. The maghemite NPs in the capsule shell
were rather monodisperse with a medium size of 7.5 nm,
indicating a unique and efficient mechanism of microcap-
sule formation. The most significant results obtained,
from Mössbauer spectroscopy, however, were that
approximately 80% of all the maghemite NPs with a
diameter between 7 and 9 nm showed a marked superpar-
amagnetic behavior which was retained up to room tem-
perature due to slow spin relaxation. This means that the
microcapsules can be directed to a predetermined site by
generating a magnetic field of a permanent magnet. In
addition, the porous nature of the core and the dissolution
of CaCO3 after the layer-by-layer coating means that
molecules trapped within the microcapsule can be
absorbed. The mild conditions under which the MNPs
incorporated in the microcapsules are synthesized may
enable the encapsulation of bioactive substances without
reducing their biological activity. Moreover, the charac-
teristics of the microcapsules obtained means that they
can be applied to the administration of drugs, in particular
treatment by hyperthermia.
Zhou et al. [4] showed that thermoplastic magnetic
bionanocomposites can be prepared from biocompatible
dextran fatty acid esters and magnetite NPs with a melting
point slightly above human body temperature. The heat-
ing response of the bionanocomposites to a high fre-
quency AMF correlated with the content of the magnetite
NPs and geometry of the sample. An optimal content of
magnetite NPs between 1 and 2 wt.% and at least 50 μm
thick enabled the heating of samples to above the melting
point. These results suggest that a controlled release sys-
tem triggered by remote magnetic heating is possible.
Advantages of this approach compared to conventional
methods include a reduced risk of leakage and a fast
response.
According to Zhu et al. [3] one way to increase the
efficacy whilst reducing the toxicity of antitumor drugs is
to deliver the drug directly to the target site and maintain
its concentration at that site for a sufficiently long thera-
peutic time. Recent strategies used to increase drug accu-
mulation in a solid target tumor also include the use of
hydrogels prepared from biopolymers. The widespread
application of hydrogels in the biomedical field is largely
due to their hydrated environment and tunable properties,
which are similar to the native extracellular matrix. In
situ forming systems are administered as aqueous solu-
tions, but become gels under physiological conditions.
Such behavior means that the hydrogels can be easily
injected and their use is most suited for localized and
minimally invasive drug delivery, where the sustained
release of the drug is required. Thermosensitive hydrogels
derived from CS and β-glycerophosphate are promising
candidates, as they are biodegradable, biocompatible,
nontoxic, and noninflammatory. However, challenges to
the application of hydrogels still exist, such as their poor
controllability, actuation, and response properties in drug
delivery. Recently, however, magnetic hydrogels have
emerged as potentially useful biocomposites due to their
superparamagnetic and responsive properties.
Miyazaki et al. [12] developed carboxymethyldexran-
Fe3O4 composites using emulsions in order to prepare
solgel microspheres for thermoseeding. Microspheres
were obtained by dehydrating the sol in a water-in-oil
emulsion. Solgel silica coatings were then prepared
using different catalysts for hydrolysis and polycondensa-
tion, as under aqueous conditions the microspheres
released a large number of iron ions. The silica coating
prepared using an acidic catalyst effectively improved
chemical durability under a simulated body environment,
whereas the coating prepared using a basic catalyst did
not. Numerous spherical NPs were observed on the micro-
spheres prepared using the basic catalyst suggesting that
the silica NPs formed on the carboxymethyldexran-Fe3O4
microspheres do not act as a continuous protective layer.
31.9 BIOCOMPOSITES FROM IRON
NANOPARTICLES—HYDROXYAPATITE
In the biomaterial sciences, the development of new mate-
rials for the effective repair of bones is an important
objective. Bone is itself a composite material made up of
60%70% inorganic mineral crystal, the major compo-
nent being HA in the form of tiny elongated crystals, and
30%40% organic matrix, consisting mostly of collagen
protein fibers [139,140]. HA, chemical formula
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Ca10(PO4)6(OH)2, has been extensively used for hard tis-
sue replacement and augmentation due to its biocompati-
bility and osteoconductive potential [141]. However, this
material is difficult to shape into the specific forms
required for bone substitution due to its hardness and brit-
tleness. Combining biopolymers with minerals to give
biomaterials with the toughness and flexibility of the bio-
polymer component and the strength and hardness of the
mineral filler has its origin in nature, for example, snail
and crab shells. Inspired by this, composites of HA and
bioorganic polymers that mimic these natural combina-
tions have ignited great interest [142].
Currently, HA has attracted much attention due to the
prospects for its use in the hyperthermic treatment of can-
cer [143]. To this end, a number of synthetic biocompati-
ble magnetic composites made from HA and magnetic
fillers have been developed, for example, spinel ferrites
[144,145], metallic iron [146], and hexagonal ferrites
[147].
Markak and Clyne [148] showed that magneto-
mechanical effects could stimulate bone growth in a
bonded array of ferromagnetic fibers. Takegami et al.
[149] prepared ferromagnetic bone cement by blending
magnetite and silica glass powders with resin that could
be used for local hyperthermia treatment in the skeletal
system. The healing of bone fractures by magnetic ther-
apy was studied by Baibekov and Khanapiyaev [150].
The preparation and application of magnetic polymer
composites for biomedical applications are of great inter-
est [51], however, these composites should be biocompat-
ible, nontoxic, and biodegradable.
Keshri et al. [151] reported the synthesis pathway and
some of the basic properties of a LSMO manganite-based
biocomposite made from LSMO NPs mixed with HA NPs
in order to ensure their biocompatibility. XRD and FTIR
results confirmed the coexistence of both phases. DC
magnetization measurements demonstrated that the
LSMOHA composite exhibited magnetic behavior
similar to that of LSMO alone. However, mixing pro-
duced a decrease in the TC and magnetization values.
Irreversibility in the temperature-dependent DC magneti-
zation was also determined by ZFC and FC curves. The
results of the magnetic hysteresis loop analysis demon-
strated that the admixture of HA preserved the magnetic
behavior of the parent sample, but with slightly lower sat-
uration field, coercive field, and magnetic moment values.
TEM results revealed that within the HALSMO com-
posite, the LSMO NPs are surrounded by HA particles
300600 nm wide. Particles of this size might prove
advantageous for in vivo drug delivery systems. However,
further research is needed in order to ensure the uniform
coating of HA around the manganite NPs.
Tkachenko and Kamzin [2] developed a method for
the synthesis of hybrid HAferrite (Fe3O4-based
magnetic filler) ceramics with higher magnetization
values than previously reported in the literature. These
authors also investigated the structure of the synthesized
hybrid ceramics, and the behavior of these materials in an
external magnetic field. Carbonated HAferrite compos-
ite particles were synthesized using a two-stage proce-
dure. The first stage involved the synthesis of ferrite
particles by coprecipitation from FeCl2 and FeCl3 aque-
ous solutions, and the synthesis of carbonated HA.
Mössbauer spectroscopy revealed that the ferrite particles
obtained consisted of magnetite (Fe3O4) and maghemite
(γ-Fe2O3). In the second stage carbonated HAferrite
composite particles were synthesized by mixing the fer-
rite, CaCO3, and H3PO4 particles, followed by annealing
at 1200C. The formation of the HAferrite composite
was confirmed by XRD, analyzing the composition of the
biocomposite, and measuring the magnetic properties.
The saturation magnetizations of the ferrite components
in the HAferrite composites were 46.4 and 48.0 emu/g
for γ-Fe2O3 and Fe3O4, respectively.
CS, poly-β(1,4)-2-amino-2-deoxy-D-glucose, is a
partly deacetylated product of chitin, which can be
extracted from crustaceans and insects. Cui et al. [18] pre-
pared novel superparamagnetic nanocomposites with vari-
ous Fe3O4/HA/CS ratios using the in situ compositing
method. The use of these nanocomposites to provide tem-
porary mechanical support for the regeneration of bone
cell ingrowth in orthopedic applications was proposed
owing to their biocompatiblity, nontoxicity, biodegradab-
lity, and inherent wound healing characteristics [152]. In
recent years, the combination of CS with biominerals to
produce versatile biomaterials has attracted increasing
interest [153]. A critical obstacle in assembling and main-
taining nanoscaled materials from NP clusters is the ten-
dency of the latter to aggregate, thus reducing the energy
associated with a high surface area to volume ratio. Cui
et al. [18] found that Fe3O4 and HA NPs with maximum
sizes under 50 nm dispersed homogeneously in the nano-
composites they prepared, and that chemical bonds
between the inorganic materials and CS molecules were
formed.
Another method employed to treat oncological dis-
eases is the magnetic hyperthermia of malignant bone
tumors. This procedure uses thermo seeds from composite
materials in a bioactive matrix (bioglass or ceramics
based on calcium phosphate) and ferrimagnetic nano- and
microparticles [154]. Brushite (CaHPO4  2H2O)-forming
calcium phosphate bone cements have the advantage of
being reabsorbable, whereas HA-forming cements are not,
but suffer from their fast, water-consuming setting reac-
tion, and low mechanical strength [5].
Matsumine et al. [155] proposed a Fe3O4-containing,
calcium phosphate-based cement for the hyperthermic
treatment of metastatic bone tumors in the femur, fibula,
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humerus, and tibia of human patients. Clinical trials were
conducted with 15 patients that had suffered metastatic
bone lesions (HT group). The results were then compared
with those for 8 patients treated by a palliative operation
(Op group), and 22 patients treated by an operation plus
radiotherapy (Op 1 RT group). The patients in the HT
group showed better radiographic outcomes than those in
the Op group and no significant differences from those in
the Op 1 RT group. Nevertheless, although the Fe3O4-
containing calcium phosphate-based cement was found to
be useful for the hyperthermic treatment of these meta-
static bone tumors, its mechanical strength is generally
lower than that of polymethyl methacrylate (PMMA)-
based cement, and consequently is not ideal for the hyper-
thermic treatment of bone tumors subjected to a high
load. To overcome this, the use of PMMA cement
containing Fe3O4 NPs has recently been proposed
[12,156,157].
Beherei et al. [5] developed a nanobrushite filler pow-
der which was then mixed with a γ-Fe2O3 powder and
loaded onto a polymeric scaffold in order to improve its
bioactivity, biodegradability, mechanical properties, and
anticancer effects. The prepared biocomposites were
then characterized in order to evaluate the homogeneity
between the two matrices, and in vitro tests were per-
formed to verify the formation of the apatite layer on the
surface of the materials. The authors obtained a multi-
functional scaffold material with bone regeneration and
anticancer properties. The results from the in vitro tests
showed that the concentrations of the Ca and P ions were
inversely proportional to that of Fe2O3. Scaffold materials
with 5% γ-Fe2O3 did not produce the hyperthermic condi-
tions required for effective treatment. However, scaffolds
with a higher content of the composite (for example 10%
and 15%) could be successfully used to generate hyper-
thermia, with activation times of about 2030 minutes (at
150 kHz).
31.10 CONCLUSIONS
Treatment with hyperthermia based on the magnetic
behavior of biocomposites, mainly INPs, has been suc-
cessfully used in the fight against cancer. This technology
has made it possible to reduce the side effects of conven-
tional treatments such as chemotherapy, as it enables
the site-specific delivery of the anticancer drugs.
Hyperthermic treatment procedures still need to be
improved, however, in order to overcome problems
related to the surface characteristics and size of the bio-
composites employed which may cause undesirable physi-
ological reactions. Advances in the preparation methods
of these biocomposites, as well as the coatings used and
the characteristics of the cancer will determine their effec-
tiveness for hyperthermia applications in the future. This
chapter sought to gather recent information on the subject
in order to promote further research in this scientific field.
Specifically, aspects related to INP-biopolymers and
INP-HAs were discussed.
ACKNOWLEDGMENTS
The authors would like to thank Consejo Nacional de
Investigaciones Cientı́ficas y Técnicas (CONICET) (Postdoctoral
fellowship internal PDTS-Resolution 2417) and Universidad
Nacional de Mar del Plata (UNMdP) for the financial support, and
Dr. Mirian Carmona-Rodrı́guez.
REFERENCES
[1] R.K. Gilchrist, R. Medal, W.D. Shorey, R.C. Hanselman, J.C. Parrott, C.B.
Taylor, Selective inductive heating of lymph nodes, Ann. Surg. 146 (4)
(1957) 596.
[2] M.V. Tkachenko, A.S. Kamzin, Synthesis and properties of hybrid
hydroxyapatiteferrite (Fe3O4) particles for hyperthermia applications,
Phys. Solid State 58 (4) (2016) 763770.
[3] X. Zhu, H. Zhang, H. Huang, Y. Zhang, L. Hou, Z. Zhang, Functionalized
graphene oxide-based thermosensitive hydrogel for magnetic hyperthermia
therapy on tumors, Nanotechnology 26 (36) (2015) 365103.
[4] M. Zhou, T. Liebert, R. Müller, A. Dellith, C. Gräfe, J.H. Clement, et al.,
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